1. Home
  2. MBBC vs NSRX Comparison

MBBC vs NSRX Comparison

Compare MBBC & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBBC

Marathon Bancorp Inc.

N/A

Current Price

$14.02

Market Cap

40.2M

Sector

Finance

ML Signal

N/A

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.01

Market Cap

32.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBBC
NSRX
Founded
1902
2019
Country
United States
Israel
Employees
35
7
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.2M
32.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MBBC
NSRX
Price
$14.02
$3.01
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$19.67
AVG Volume (30 Days)
18.3K
53.9K
Earning Date
05-12-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$47.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.95
$1.98
52 Week High
$15.75
$9.99

Technical Indicators

Market Signals
Indicator
MBBC
NSRX
Relative Strength Index (RSI) 54.56 48.07
Support Level $12.90 $2.04
Resistance Level $15.57 $3.48
Average True Range (ATR) 0.54 0.28
MACD 0.02 0.01
Stochastic Oscillator 77.72 32.03

Price Performance

Historical Comparison
MBBC
NSRX

About MBBC Marathon Bancorp Inc.

Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: